clinical trial · NCT05453903
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
Janssen Research & Development, LLC·phase1·active not recruiting·n = 196
Leukemia, Myeloid, AcuteBleximenibVenetoclax (VEN)Azacitidine (AZA)CytarabineDaunorubicin or Idarubicin
brief summary
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of bleximenib in combination with AML directed therapies at the RP2D(s) (dose expansion).
started
Oct 4, 2022
primary completion
Oct 30, 2026
completion
Jun 30, 2027
last updated
Sep 25, 2026
official title
A Phase 1b Study of Bleximenib in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol